Management of chronic venous insufficiency of the lower extremities
https://doi.org/10.21518/1995-1477-2018-3-4-36-41
Abstract
The article presents up-to-date information about epidemiology, pathogenesis and clinical manifestations of chronic venous diseases and chronic venous insufficiency of the lower extremities. It discusses the mechanism of action of various phlebotrophic drugs intended for the treatment of symptoms of chronic venous diseases and chronic venous insufficiency and describes the advantages of micronized purified flavonoid fraction for the treatment of all clinical classes of chronic venous diseases.
About the Author
M. N. Kudykin
Russian Association of Phlebologists
Russian Federation
Nizhniy Novgorod
Russian Federation
Nizhniy Novgorod
References
1. Shlyakova AA, Korneva KG, Kudykin MN, Peretyagin PV. Features of microcirculation of the lower extremities in patients with type 2 diabetes mellitus in combination with chronic venous insufficiency. Terapevt, 2014, 1: 15-18
2. Bergan JJ, Schmid-Schonbein GW, Coleridge-Smith PD. Chronic venous disease. N Engl J Med, 2006, 355(3): 488-496.
3. Nicolaides A, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol, 2014, 33(2): 87-208.
4. Allegra C, Antignani P-L, Bergan JJ et al. The «С» of CEAP: Suggested definitions and refinements: An international Union of Phlebology conference of experts. J Vasc Surg, 2003, 37(1): 129-131.
5. Rabe E, Guex J-J, Puskas A, Scuderi A, Fernandez Quesada F, The VCP Coordinators Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol, 2012, 31(2): 105-115.
6. Eklof Bo, Perrin M, Konstantinos T Delis et al. Up-date terminology of chronic venous disorders: The VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg, 2009, 49: 498-501.
7. Bogachev VYu. Modern pharmacotherapy of chronic venous insufficiency of the lower extremities. Farmatsevticheskiy Vestnik, 2006, 10 (2): 54-59
8. Ruckley CV, Fowkes FGR, Bradbury AW. Venous Disease. Epidemiology, Management and Delivery of Care. Springer. 1999, 278.
9. Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre crosssectional study in 40095 patients. Phlebology, 2003, 81: 110122.
10. Langer RD, Ho E, Deneberg JO et al. Relation-ship between symptoms and venous disease. Arch Int Med, 2005, 165: 14201424.
11. Labropoulos N, Stansby G. Venous and Lymphatic Diseases. Taylor & Francis. 2006, 559.
12. Schmid-Schonbein GW, Granger DN. Molecular Basis for Microcirculatory Disorders. Springer. 2003, 640.
13. Nicolaides AN, Allegra C, Bergan J et al. Management of Chronic Venous Disorders of the Lower Limbs Guidelines According to Scientific Evidence. International Angiology, 2008, 27: 1-59.
14. Ramelet A-A, Perrin M, Kern P, Bounameaux H. Phlebology, 5-th edition, Elsevier Masson. 2008. 565.
15. Davies AH. Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2015 Nov 17. pii: S1078-5884(15)00699-1. doi: 10.1016/j.ejvs.2015.09.024.
16. Varicose Veins in the Legs: The Diagnosis and Management of Varicose Veins. National Clinical Guideline Centre (UK). London: National Institute for Health and Care Excellence (UK), 2013 Jul.
17. Russian clinical guidelines for the diagnosis and treatment of chronic venous diseases. Flebologiya. 2018, 3: 146240.
18. Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol, 2005 Jan, 3(1): 1-9.
19. Jantet G. RELIEF Study Group. Chronic Venous Insufficiency: Worlwide Results of the RELIEF Study. Angiology, 2002, 53: 245256.
20. Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol, 2015 Oct, 34(5): 428-36. Epub 2015 May 14.
21. Pitsch F. Assessment of treatment efficacy on venous symptoms: the example of Detralex. Phlebolymphology, 2008, 15: 137-142.
22. Belczak SQ, Sincos IR, Campos W, Beserra J, Nering G, Aun R. Venoactive drugs for chronic venous disease: A randomized, double-blind, placebo-controlled paralleldesign trial. Phlebology, 2014 Aug, 29(7): 454-60. doi: 10.1177/0268355513489550. Epub 2013 May 16.
23. Colerige-Smith P, Lok C, Ramelet AA. Venous leg ulcer: metaanalysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg, 2005, 30: 198-208.
24. Chesnokova NN, Kononova SV, Zaporozhskaya LI, Kudykin MN. Research of the regional drug market segment for the treatment and prevention of varicose veins of lower extremities. Meditsinsky Almanakh, 2015, 4 (39): 205-209.
25. Patient Information Leaflet: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=857a69bd-2c44-43dc-b38c2eaff93ab244&t.
26. Colerige-Smith P. From Skin Disorders to Venous Leg Ulcers: Pathophysiology and Efficacy of Daflon 500 rngin Ulcer Healing. Angiology, 2003, 54(Suppl 1): 45-50.
27. Handbook of venous disorders. 7-nd ed. Guidelines Am Venous Forum 2017, 557.
28. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/level/ section: Incomes, expenses and living conditions of households
Review
For citations:
Kudykin M.N. Management of chronic venous insufficiency of the lower extremities. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2018;(3-4):36-41. (In Russ.) https://doi.org/10.21518/1995-1477-2018-3-4-36-41
Views:
4595
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 